The first CAD/CAM milled Obstructive Sleep Apnea device, MicrO2 is FDA cleared and offers dentists a new, innovative option for treating the growing number of patients diagnosed with Obstructive Sleep Apnea (OSA).
“Dentists are the front line for screening and managing patients with Obstructive Sleep Apnea,” noted Kim Bradshaw, CEO and President of MicroDental Laboratories. “Many of our partner dentists asked for a small, precise, and easy to use Mandibular Advancement Device. The MicrO2 device has been designed from the very beginning with these goals in mind.”
“I believe the MicrO2 will revolutionize dental sleep medicine,” stated Dr. William G. Dickerson, DDS, FAACD, LVIM. “I can honestly say that I don’t think there is a better appliance out there. With its lingual-less design, airway constriction preventing fins, and unobtrusive size, this device is a winner.”
Featuring a patent pending design and a precision milling production process, the MicrO2 is able to utilize a PMMA material that is cured under controlled conditions. These aspects allow the MicrO2 to be small yet strong, precise, and predictable. The MicrO2 also features a unique approach to titration that is intended to make the device easier to use for the dentist and the patient.
“The MicrO2 does not require patients to manage any mechanical adjustments, such as turning screws, or changing positions with elastics. Instead the MicrO2 comes with one pair of Upper and Lower arches set to the prescription, and a second pair set in any amount of advancement increments. Advancements are easily achieved by simply removing the current Upper or Lower arch device and inserting the next advancement device in the MicrO2 series,” commented Laura Sheppard, Sr. Director of Compliance and Regulatory Affairs for MicroDental.
“It is important to treat Obstructive Sleep Apnea while also minimizing the risk of TMJ and other related cranio-facial complications,” testifies Dr. Anne-Maree Cole, BDSC, LVIM of Queensland, Australia. “The lingual-less design of the MicrO2 device ensures that tongue space is optimized and the comfortable, balanced, physiologic jaw position is maintained. The CAD/CAM design optimizes outcome but minimizes bulk – a true break through advancement in the treatment of snoring and Sleep Apnea.”
Obstructive Sleep Apnea is one of the fastest developing frontiers in dentistry. A report by the Institute of Medicine estimates that 50-70 Million Americans suffer from chronic sleep disorders. More than 18 million Americans have Obstructive Sleep Apnea. Obstructive Sleep Apnea has been linked with snoring, memory loss, headaches, depression, and an increased risk of stroke, heart problems, and motor vehicle accidents.
“MicroDental Laboratories has a legacy of partnering with dentists who are committed to enhancing the lives of their patients,” noted Len Liptak, VP of Sales and Marketing for MicroDental. “With our FDA-cleared MicrO2 device, we look forward to partnering with these dentists as they manage the growing number of patients who are diagnosed with this serious condition.”